0.01% (w/v) Sodium Azide. 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Quelle:
Golden Syrian Hamster
Reinheit:
Hamster IgG whole molecule was prepared from normal serum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Hamster IgG whole molecule was assayed by immunoelectrophoresis resulted in a single precipitin arc against anti-GS Hamster IgG and anti-GS Hamster Serum.
Formulierung:
Lyophilized
Application Verdünnung:
ELISA: User Optimized, IHC: User Optimized, WB: User Optimized
Anwendungsbeschreibung:
Biological Origin: Golden Syrian Hamster. Application Notes: Hamster IgG whole molecule has been tested by SDS-Page and can be utilized as a control or standard reagent in Western Blotting and ELISA experiments. Reconstitution Buffer: Restore with deionized water (or equivalent). Reconstitution Volume: 1.0 mL
Anti-CD154-facilitated alloengraftment is multilineage. Twenty mice from 2 representative experiments shown in Figure 1 were phenotyped at 120 days after BMT for donor-host origin of CD4+ and CD8 + T cells, CD19 + B cells, and MAC-1 + myeloid cells. On the x-axis are shown the host and donor proportions of each of the lineages. ▪ indicates the proportion of each lineage of host origin, ▥, the proportion of each lineage that is of donor origin. On the y-axis is shown the percentage of PBLs of each lineage. Irrelevant hIgG-treated mice had no detectable donor chimerism and thus are composed entirely of host-type cells. Note that most CD4+ T cells, CD19 + B cells, and MAC-1 + myeloid cells in anti-CD154-treated mice are of donor origin. In contrast, most of the CD8 + T cells are of host origin.
Anti-CD40L mAb alone or in combination with (A) sirolimus or (B) CsA results in long-term multilineage engraftment.
Anti-PD-1 antibody plus radiation therapy (RT) cures mice with intracranial GL261-luc tumors. (A) Experimental timeline. (B) Luciferase imaging of 4 distinct mice per treatment arm before treatment (day 7) and after treatment (day 21), divided by treatment group. All images at same scale. All mice individually matched on days 7 and 21. (C) Kaplan-Meier survival curve. P 6 mice per arm.
Combination therapy with Cy/GVAX and PD-1 or PD-L1 blockade improves clinical outcomes in a PDA mouse model. Anti-PD-1, anti-PD-L1 or IgG (5 mg/kg IP) were administered IP twice weekly until death starting on day 3. (B) Kaplan-Meier survival curves of mice that were implanted with PDA cells and were treated with different combinations of Cy, GVAX and the alphaPD-1 antibody. The percentages of mice that remained disease free at day 90 following tumor implantation and therapy with (C) Cy, GVAX and/or alphaPD-1 or (D) Cy, GVAX and alphaPD-L1 are shown. All the p values were yielded by comparing GVAX and/or alphaPD-1/alphaPD-L1 treatment groups with IgG treated group. (E) Kaplan-Meier survival curves of mice that were implanted with Panc02 cells via hemispleen technique and treated with different combinations of Cy, GVAX and alphaPD-L1 antibody. Data are represented as results obtained from experiments with 8-10 mice per group that were repeated at least twice.
SDS-PAGE Results of Golden Syrian Hamster IgG Whole Molecule. Lane 1: Golden Syrian Hamster IgG Whole Molecule, Reduced [5.0 µg]. Lane 2: Opal Pre-Stained Molecular Weight Marker. Lane 3: Golden Syrian Hamster IgG Whole Molecule, Non-Reduced [5.0 µg]. 4-20% gel, Coomassie stained.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
